Chemomab Therapeutics (CMMB) Cash & Equivalents (2017 - 2025)

Chemomab Therapeutics (CMMB) has 9 years of Cash & Equivalents data on file, last reported at $7.6 million in Q4 2025.

• Quarterly Cash & Equivalents rose 24.59% year-over-year to $7.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.6 million (up 24.59% YoY) and the FY2025 annual result came in at $7.6 million, up 24.59% from the prior year.
• Cash & Equivalents climbed to $7.6 million in Q4 2025, from $7.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $58.2 million in Q1 2021 to a low of $4.7 million in Q1 2024.
• A 5-year average of $15.3 million and a median of $9.6 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2021 — Cash & Equivalents jumped 457.68% — and 2022, when it sank 78.06%.
• Tracing CMMB's Cash & Equivalents over 5 years: stood at $15.2 million in 2021, then decreased by 10.98% to $13.5 million in 2022, then slumped by 31.27% to $9.3 million in 2023, then tumbled by 34.66% to $6.1 million in 2024, then climbed by 24.59% to $7.6 million in 2025.
• The last three Cash & Equivalents figures came in at $7.6 million (Q4 2025), $7.0 million (Q3 2025), and $5.6 million (Q2 2025), per Business Quant data.